Logo wahanariau.com
  2. Sapu biosciences

Sapu biosciences

Index
Globenewswire

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

Rabu, 13 Mei 2026 - 22:20:36 Wib
Globenewswire

Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

Senin, 16 Februari 2026 - 06:25:34 Wib
Globenewswire

Sapu BioScience Highlights TGFB2-Guided Strategy to Enhance Taxane Therapies, Reinforcing the Rationale for Sapu-001

Kamis, 18 Desember 2025 - 07:24:01 Wib
Globenewswire

Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Jumat, 05 Desember 2025 - 21:56:27 Wib
Globenewswire

Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Jumat, 05 Desember 2025 - 13:17:58 Wib
Globenewswire

Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Kamis, 04 Desember 2025 - 12:44:33 Wib
Globenewswire

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Kamis, 25 September 2025 - 23:54:24 Wib
Globenewswire

SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Sabtu, 19 Juli 2025 - 01:35:51 Wib